Hepatic Cirrhosis Clinical Trial
Official title:
A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy
Verified date | June 2021 |
Source | Mallinckrodt |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.
Status | Completed |
Enrollment | 50 |
Est. completion date | July 14, 2020 |
Est. primary completion date | July 14, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Key Inclusion Criteria: A potential participant may only be included if (at screening), he/she: 1. Understands the study and has signed informed consent 2. Is an adult, not pregnant or lactating 3. Has cirrhosis of the liver 4. Has had 1 instance of HE within 12 months 5. Has hyperammonaemia defined as =37 µmol/L at screening Key Exclusion Criteria: A potential participant will be excluded if (at screening), he/she: 1. Has contraindicated allergies 2. Expects liver transplant within 1 month 3. Has had a liver shunt within the last 3 months 4. Has inadequate kidney, gastrointestinal, or cardiac function 5. Has cancer, infection, lab abnormalities, or any other condition that, per protocol or in the opinion of the investigator might compromise: 1. the safety and well-being of the participant or potential offspring 2. the safety of study staff 3. the analysis of results |
Country | Name | City | State |
---|---|---|---|
Puerto Rico | Fundacion de Investigacion (Research Foundation) | San Juan | |
United States | Southern California Research Center | Coronado | California |
United States | Inland Empire Clinical Trials | Rialto | California |
United States | Global Clinical Professionals | Saint Petersburg | Florida |
United States | American Research Corporation at the Texas Liver Institute | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Mallinckrodt |
United States, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ammonia Plasma Levels at Baseline and Day 5 | This test measures the level of ammonia in your blood. Ammonia, also known as NH3, is a waste product made by your body during the digestion of protein. Normally, ammonia is processed in the liver, where it is changed into another waste product called urea. Urea is passed from the body in urine.
If your body cannot process or eliminate ammonia, a lab test of a blood sample shows it has built up in the bloodstream. High ammonia levels in the blood can lead to serious health problems, including hepatic encephalopathy. |
Baseline, Day 5 | |
Secondary | Number of Participants With Adverse Events by the End of the Trial | End of trial is defined as 7 (+/-3) days after last study treatment | within 15 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
Completed |
NCT02138253 -
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
|
Phase 2 | |
Recruiting |
NCT02652351 -
Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
|
Phase 1 | |
Completed |
NCT00794482 -
Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
|
Phase 3 | |
Completed |
NCT00856713 -
Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02163512 -
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
|
||
Completed |
NCT00857480 -
Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin
|
Phase 1 | |
Completed |
NCT00006164 -
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
|
Phase 3 | |
Completed |
NCT03486912 -
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
|
Phase 2 | |
Completed |
NCT00698464 -
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
|
Phase 1 | |
Completed |
NCT02778425 -
The Treatment of Hepatocirrhosis and Portal Hypertension
|
N/A | |
Completed |
NCT03445208 -
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
|
Phase 1 | |
Completed |
NCT03420768 -
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
|
Phase 2 | |
Completed |
NCT03804593 -
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
|
||
Completed |
NCT02230683 -
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
|
Phase 2 | |
Completed |
NCT02230670 -
A Study of IDN-6556 in Subjects With Liver Cirrhosis
|
Phase 2 | |
Completed |
NCT01135628 -
Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
|
N/A | |
Completed |
NCT00856869 -
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
|
Phase 1/Phase 2 |